---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-025241"
form_type: "8-K/A"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:38:38.739473+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Vanda board rejects conditional resignation of director Chrousos after less-than-majority vote

## Summary
- Director Phaedra S. Chrousos received less than majority votes at 2024 annual meeting, tendered conditional resignation.
- Board (excluding Chrousos) unanimously voted May 22, 2024 to reject resignation, citing qualifications and proxy advisory firm's recommendation related to Rights Agreement.
- Chrousos will continue as director until Vanda's 2027 annual meeting or until successor elected.

## SEC filing metadata
- accession: 0001628280-24-025241
- form_type: 8-K/A
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828024025241/0001628280-24-025241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828024025241/vnda-20240517.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-025241
- JSON: https://secwatch.observer/filing/0001628280-24-025241.json
- Plain text: https://secwatch.observer/filing/0001628280-24-025241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.